Literature DB >> 8100523

Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum.

R Mentlein1, B Gallwitz, W E Schmidt.   

Abstract

Peptides of the glucagon/vasoactive-intestinal-peptide (VIP) peptide family share a considerable sequence similarity at their N-terminus. They either start with Tyr-Ala, His-Ala or His-Ser which might be in part potential targets for dipeptidyl-peptidase IV, a highly specialized aminopeptidase removing dipeptides only from peptides with N-terminal penultimate proline or alanine. Growth-hormone-releasing factor (1-29)amide and gastric inhibitory peptide/glucose-dependent insulinotropic peptide (GIP) with terminal Tyr-Ala as well as glucagon-like peptide-1(7-36)amide/insulinotropin [GLP-1(7-36)amide] and peptide histidine methionine (PHM) with terminal His-Ala were hydrolysed to their des-Xaa-Ala derivatives by dipeptidyl-peptidase IV purified from human placenta. VIP with terminal His-Ser was not significantly degraded by the peptidase. The kinetics of the hydrolysis of GIP, GLP-1(7-36)amide and PHM were analyzed in detail. For these peptides Km values of 4-34 microM and Vmax values of 0.6-3.8 mumol.min-1.mg protein-1 were determined for the purified peptidase which should allow their enzymic degradation also at physiological, nanomolar concentrations. When human serum was incubated with GIP or GLP-1(7-36)amide the same fragments as with the purified dipeptidyl-peptidase IV, namely the des-Xaa-Ala peptides and Tyr-Ala in the case of GIP or His-Ala in the case of GLP-1(7-36)amide, were identified as the main degradation products of these peptide hormones. Incorporation of inhibitors specific for dipeptidyl-peptidase IV, 1 mM Lys-pyrrolidide or 0.1 mM diprotin A (Ile-Pro-Ile), completely abolished the production of these fragments by serum. It is concluded that dipeptidyl-peptidase IV initiates the metabolism of GIP and GLP-1(7-36)amide in human serum. Since an intact N-terminus is obligate for the biological activity of the members of the glucagon/VIP peptide family [e. g. GIP(3-42) is known to be inactive to release insulin in the presence of glucose as does intact GIP], dipeptidyl-peptidase-IV action inactivates these peptide hormones. The relevance of this finding for their inactivation and their determination by immunoassays is discussed.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8100523     DOI: 10.1111/j.1432-1033.1993.tb17986.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  232 in total

1.  Circulating GLP-1 and CCK-8 reduce food intake by capsaicin-insensitive, nonvagal mechanisms.

Authors:  Jingchuan Zhang; Robert C Ritter
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2011-10-26       Impact factor: 3.619

Review 2.  Bariatric surgery evolution from the malabsorptive to the hormonal era.

Authors:  Ehab Akkary
Journal:  Obes Surg       Date:  2012-05       Impact factor: 4.129

3.  Comparative effects of the endogenous agonist glucagon-like peptide-1 (GLP-1)-(7-36) amide and the small-molecule ago-allosteric agent "compound 2" at the GLP-1 receptor.

Authors:  Karen Coopman; Yan Huang; Neil Johnston; Sophie J Bradley; Graeme F Wilkinson; Gary B Willars
Journal:  J Pharmacol Exp Ther       Date:  2010-05-27       Impact factor: 4.030

4.  cAMP-independent effects of GLP-1 on β cells.

Authors:  Jelena Kolic; Patrick E MacDonald
Journal:  J Clin Invest       Date:  2015-11-16       Impact factor: 14.808

5.  Application of pharmacometric approaches to evaluate effect of weight and renal function on pharmacokinetics of alogliptin.

Authors:  Himanshu Naik; Richard Czerniak; Majid Vakilynejad
Journal:  Br J Clin Pharmacol       Date:  2016-02-22       Impact factor: 4.335

6.  Novel hydrazine derivatives as selective DPP-IV inhibitors: findings from virtual screening and validation through molecular dynamics simulations.

Authors:  Omprakash Tanwar; Girdhar Singh Deora; Lalima Tanwar; Gautam Kumar; Sridhara Janardhan; Mumtaz Alam; Mymoona Akhter
Journal:  J Mol Model       Date:  2014-04-01       Impact factor: 1.810

7.  Behavioural profile of exendin-4/naltrexone dose combinations in male rats during tests of palatable food consumption.

Authors:  F L Wright; R J Rodgers
Journal:  Psychopharmacology (Berl)       Date:  2014-02-28       Impact factor: 4.530

Review 8.  Glucagon-like peptide 1 (GLP-1).

Authors:  T D Müller; B Finan; S R Bloom; D D'Alessio; D J Drucker; P R Flatt; A Fritsche; F Gribble; H J Grill; J F Habener; J J Holst; W Langhans; J J Meier; M A Nauck; D Perez-Tilve; A Pocai; F Reimann; D A Sandoval; T W Schwartz; R J Seeley; K Stemmer; M Tang-Christensen; S C Woods; R D DiMarchi; M H Tschöp
Journal:  Mol Metab       Date:  2019-09-30       Impact factor: 7.422

9.  Suppression of food intake by glucagon-like peptide-1 receptor agonists: relative potencies and role of dipeptidyl peptidase-4.

Authors:  Lene Jessen; Benedikt A Aulinger; Jonathan L Hassel; Kyle J Roy; Eric P Smith; Todd M Greer; Stephen C Woods; Randy J Seeley; David A D'Alessio
Journal:  Endocrinology       Date:  2012-10-02       Impact factor: 4.736

10.  Crystal structure of the GLP-1 receptor bound to a peptide agonist.

Authors:  Ali Jazayeri; Mathieu Rappas; Alastair J H Brown; James Kean; James C Errey; Nathan J Robertson; Cédric Fiez-Vandal; Stephen P Andrews; Miles Congreve; Andrea Bortolato; Jonathan S Mason; Asma H Baig; Iryna Teobald; Andrew S Doré; Malcolm Weir; Robert M Cooke; Fiona H Marshall
Journal:  Nature       Date:  2017-05-31       Impact factor: 49.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.